Research programme: ubiquitin ligase modulators - Nurix
Alternative Names: UPS modulatorsLatest Information Update: 28 Sep 2022
At a glance
- Originator Nurix
- Developer Celgene Corporation; Nurix
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin protein ligase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Cancer in USA (PO)
- 28 Aug 2020 No recent reports of development identified for research development in Inflammation in USA
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb